Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News European Commission grants marketing approval for BAH’s Neptra ear drops

European Commission grants marketing approval for BAH’s Neptra ear drops

16th December 2019

Bayer Animal Health’s (BAH) state-of-the-art Neptra ear drops, for the treatment of acute exacerbations of recurrent otitis or acute canine otitis externa in dogs, have been granted marketing approval by the European Commission. The single dose ear drops, which contain mometasone furoate, florfenicol and terbinafine hydrochloride, will be made available early in the New Year.

Mario Andreoli, BAH’s Head of Marketing, stated: “Neptra offers a key advantage unlike competing products, it requires just one dose administered by the veterinarian in the practice. No at home applications by the dog owner are required. The treatment stays in the hands of the veterinarian and therefore, allows full control over compliance.”

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.